8,541 trials (keyword fallback)
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Periampullary Cancers With Obstructive Jaundice · Pancreas Head Cancer · Bile Duct Cancer
Primary: Incidence of Infectious Complications After Biliary Drainage — 11; 5 participants
Biliary Tract Neoplasms · Cholangiocarcinoma · Bile Duct Cancer
Primary: Progression Free Survival (PFS) — 4.54 Months
Pancreatic Cancer
Primary: Sustained Biliary Drainage, Defined as Absence of Reinterventions for the Management of Biliary Obstructive Symptoms — 39; 43 Participants — p=<0.01
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Biliary Tract Cancer
Primary: Objective Response Rate (ORR) - Part 1 — 0; 0; 6; 3 Participants
Biliary Tract Neoplasms
Primary: The Percentage of Patients Alive and Without Progression at 6 Months Following the Initiation of Treatment — 59.4; 21.2 percentage of participants
Women's Health · HIV Infection · Genital Diseases, Female
Primary: CD4+ to CD8+ T Cell Ratio in Cervical Biopsies — 0.46; 0.52 Cervical CD4+:CD8+ T cell ratio — p=0.6
Pancreatic Neoplasms · Bile Duct Neoplasms
Primary: Overall Response Rate — 1; 1; 3; 1 participants
Pancreatic Cancer
Primary: Assess the Occlusion Rates, Attempted Surgical Resection or Death of Plastic, Covered, and Uncovered Biliary Stents in Patients Presenting With Malignant Biliary…
Biliary Stricture
Primary: Count of Participants With Stent Patency at 90 Days — 22 Participants
Biliary Strictures
Primary: Safe Stent Removal — 33 Participants
Cancer
Primary: Number of Participants With Indicated Non-progressive Disease as Assessed by Investigator Per Response Evaluation Criteria In Solid Tumor Version 1.1 (RECIST 1.1) at…
Gastrointestinal Cancer · Biliary Tract Cancer
Primary: Part 1: Establish the Maximum Tolerated Dose (MTD) — 100 mg
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent